Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 2 1Phase 1 1

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 72Genitourinary 56Plasma cell 29Sarcoma 16Thoracic 15CNS 7Gastrointestinal 6Other hematologic neoplasm 5Lymphoid 5Gynecologic 5Tumor-Agnostic 4Myeloid 2Other solid neoplasm 1Other neoplasm 1Head & Neck 1

Conditions

Neoplasms 2Neoplasm, Residual 1Adenocarcinoma 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Zoledronic Acid × Tumor-Agnostic × Clear all
NCT02069340 2017-04-11

Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

University of Southern California

Phase NA Withdrawn
Tumor-Agnostic

Neoplasms

NCT00241111 2017-03-06

Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis

Novartis

Phase 4 Completed
148 enrolled
Tumor-Agnostic

Neoplasms

NCT00892242 2014-09-22

Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer

Washington University School of Medicine

Phase 1 Terminated
24 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated
96 enrolled
Tumor-Agnostic

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡